Biomarin Pharmaceutical (BMRN) Inventory (2009 - 2026)

Biomarin Pharmaceutical has disclosed Inventory across 18 years of filings, most recently posting $1.3 billion for Q1 2026.

• Quarterly Inventory changed 0.13% year-over-year to $1.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 billion (changed 0.13% YoY) and the FY2025 annual result came in at $1.3 billion, up 5.37% from the prior year.
• Inventory retreated to $1.3 billion in Q1 2026, from $1.3 billion in the prior quarter.
• Over five years, Inventory peaked at $1.4 billion in Q3 2025 and troughed at $786.4 million in Q1 2022.
• A 5-year average of $1.1 billion and a median of $1.1 billion in 2024 frame the typical range for Inventory.
• Annual changes were most pronounced in 2024 — Inventory climbed 23.84% — and 2026, when it dropped 0.13%.
• Tracing BMRN's Inventory over 5 years: stood at $894.1 million in 2022, then advanced by 23.83% to $1.1 billion in 2023, then advanced by 11.33% to $1.2 billion in 2024, then gained by 5.37% to $1.3 billion in 2025, then fell by 1.98% to $1.3 billion in 2026.
• Business Quant data shows BMRN's Inventory at $1.3 billion in Q1 2026, $1.3 billion in Q4 2025, and $1.4 billion in Q3 2025.